4WEALTH Advisors Inc. Sells 2,177 Shares of Johnson & Johnson (NYSE:JNJ)

4WEALTH Advisors Inc. cut its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 19.6% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 8,956 shares of the company's stock after selling 2,177 shares during the period. Johnson & Johnson makes up approximately 1.6% of 4WEALTH Advisors Inc.'s investment portfolio, making the stock its 15th largest holding. 4WEALTH Advisors Inc.'s holdings in Johnson & Johnson were worth $1,485,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the stock. Brighton Jones LLC grew its position in shares of Johnson & Johnson by 13.9% in the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock valued at $7,502,000 after purchasing an additional 6,332 shares during the last quarter. Hudson Value Partners LLC lifted its stake in Johnson & Johnson by 2.5% during the fourth quarter. Hudson Value Partners LLC now owns 41,403 shares of the company's stock worth $5,648,000 after purchasing an additional 1,022 shares during the last quarter. Runnymede Capital Advisors Inc. bought a new stake in Johnson & Johnson during the fourth quarter worth $38,000. Guardian Partners Inc. bought a new stake in Johnson & Johnson during the fourth quarter worth $13,533,000. Finally, Banco de Sabadell S.A lifted its stake in Johnson & Johnson by 1.3% during the fourth quarter. Banco de Sabadell S.A now owns 14,660 shares of the company's stock worth $2,119,000 after purchasing an additional 181 shares during the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Stock Up 2.2%

NYSE:JNJ traded up $3.54 on Tuesday, hitting $167.90. The stock had a trading volume of 9,277,637 shares, compared to its average volume of 8,146,116. The company has a quick ratio of 1.03, a current ratio of 1.26 and a debt-to-equity ratio of 0.49. The company has a market cap of $403.99 billion, a PE ratio of 17.96, a P/E/G ratio of 2.08 and a beta of 0.41. The business's fifty day moving average is $154.29 and its 200 day moving average is $155.12. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a return on equity of 33.07% and a net margin of 25.00%. The business had revenue of $23.74 billion for the quarter, compared to analysts' expectations of $22.85 billion. During the same period in the prior year, the firm posted $2.82 EPS. The firm's quarterly revenue was up 5.8% on a year-over-year basis. On average, equities research analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be given a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.10%. Johnson & Johnson's dividend payout ratio (DPR) is currently 55.61%.

Analysts Set New Price Targets

Several equities analysts recently weighed in on JNJ shares. Sanford C. Bernstein reaffirmed a "market perform" rating on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Bank of America lifted their target price on shares of Johnson & Johnson from $161.00 to $175.00 and gave the stock a "neutral" rating in a research report on Thursday, July 17th. Piper Sandler reissued an "overweight" rating on shares of Johnson & Johnson in a research report on Thursday, July 17th. Leerink Partnrs cut shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, May 13th. Finally, Leerink Partners lowered shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and decreased their price target for the stock from $169.00 to $153.00 in a research note on Tuesday, May 13th. Eleven equities research analysts have rated the stock with a hold rating, nine have given a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, Johnson & Johnson has a consensus rating of "Moderate Buy" and a consensus price target of $172.87.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.